Posts

Landscape of Kinase gene fusions in cancers

Tyrosine kinases such as ALK, RET and ROS1 are often activated by translocations or chromosomal rearrangements that result in increased oncogenic activity and are attractive candidates for targeted therapy. In our #biobank, we have identified many patient samples harbouring ALK, RET and ROS1 rearrangements by NGS.

FDA approved drugs such as Crizotinib (Xalkori, #Pfizer), Ceritinib (Zykadia, #Novartis), and Alectinib (Alecensa, #Roche) that target the kinase activity of ALK; Pralsetinib (Gavreto, Roche) targeting RET fusions in NSCLC; Entrectinib (Rozlytrek, Roche) for ROS1+ metastatic NSCLCs, and novel drugs in #clinicaltrials offer promising therapeutic approaches for not just lung but also breast, colorectal and other solid tumours.

Targeted therapy in Gliomas based on genetic screening ?

Mutations and mutation analysis in cancer are very useful for specific #therapies that target the #mutations and spare normal cells. #precisionmedicine, especially #precisiononcology is a well-established option for #cancertreatment. With novel therapies and #therapeutics being discovered with increasing frequency, the treatment options available for combating cancers are increasingly dependent on #genomicmedicine. With adequate #cancerawareness and #cancercare along with a helping hand, defeating this deadly disease has never looked more promising.

 

American Brain Tumor Association, 

Children’s Brain Tumor Foundation

International Brain Tumour Alliance

A Kids’ Brain Tumor Cure Foundation (PLGA Foundation)

National Brain Tumor Society

Pediatric Brain Tumor Foundation

ABC2 (Accelerate Brain Cancer Cure)

Mutations in Lung Cancer Driving Targeted Therapy

In recent years, personalized medicine has begun to bring new hope to people with lung cancer, especially non-small cell lung cancer. Personalized medicine involves looking at the cells obtained from a biopsy to see if there are any genetic mutations — changes in your genes — that could be linked to the type of cancer you have. Because certain chemotherapy drugs are either more or less effective than others against tumors with specific mutations, molecular analysis of your tumor, also called genomic testing, can help determine which therapies will be most likely to benefit you. The most common genetic changes that are tested for in lung cancer are in the genes EGFR, ALK, ROS, PDL 1 and KRAS.